ABSTRACT
Background: to evaluate the impact of COVID-19 on the course of allergic diseases in children. Method(s): 32 children with allergic diseases who had a coronavirus infection or their parents were surveyed. The questionnaire consisted of questions about the severity of an allergic disease, the severity and complications of a SARS-CoV- 2 infection, the amount of therapy during infection and after infection. The age of patients is from 5 to 16 years (boys 62%, girls 38%). Result(s): Among the respondents were 53.1% (17 patients) with allergic rhinoconjunctivitis (AlRC), 34.3% (11) with atopic bronchial asthma (ABA), 9.5% (3) with atopic dermatitis (AtD) and 3.1% (1) with a history of acute spontaneous urticaria (OK). 71.9% of patients suffered COVID-19 in mild, 25% in moderate and 3.1% in severe forms. Complications: 11 patients were diagnosed pneumonia with lung damage of less than 25%, 1 case of acute urticaria. The analysis of the effect of COVID-19 on the course of allergic diseases was carried out among patients (25 people) who were in remission before infection: with AlRC -15, ABA -8, AtD-2 patients. Patients with AlRC against the background of COVID-19 disease in 40% cases had increase in symptoms, 33.3% noted a preservation of exacerbation after 1 month after the disease, 26.7% after 3 months. Patients with ABA had increase symptoms against the background of COVID-19 occurs in 37.5%, 25% of cases -1 month after the disease, 12.5% of cases after 3 months, Symptoms did not bother and after 6 months. 1 patient with AtD disease had an exacerbation of dermatitis during of COVID-19 and 1 month after infections. Patients who had an exacerbation of an allergic disease against the background of COVID-19, changed drug treatment on a step upper. Reducing the dose of the drugs and and the volume of drug therapy was possible only 3 months after the infection Conclusion(s): Children with allergic diseases have SARS-CoV- 2 occurs in a mild form in most cases. COVID-19 causes exacerbation of AlRC, ABA, AtD in more than 1/3 of patients. Acute urticaria was presented as a complication in one case. Exacerbation of allergopathology against the background of COVID 19 requires a transition to a step above drug therapy for 3 months. Control over the symptoms of allergic diseases is observed 3 to 6 months after the infection.